{"id":"measles-vaccine","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Fever"},{"rate":"5","effect":"Rash"},{"rate":"10-20","effect":"Local injection site reactions (pain, erythema, swelling)"},{"rate":"1-3","effect":"Mild thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL2109211","moleculeType":"Vaccine component"},"_dailymed":{"setId":"0a9e384f-e717-436b-b9a0-15e53cef0862","title":"M-M-R II (MEASLES, MUMPS, AND RUBELLA VIRUS VACCINE LIVE) INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION STERILE DILUENT (STERILE WATER) INJECTION [MERCK SHARP & DOHME LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains live attenuated (weakened) measles virus that replicates in the body without causing disease, triggering both humoral (antibody) and cell-mediated immune responses. This primes the immune system to recognize and rapidly eliminate wild-type measles virus upon exposure, providing long-lasting protection against measles infection.","oneSentence":"The measles vaccine stimulates the immune system to produce antibodies and cellular immunity against the measles virus, preventing infection and disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:05.160Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of measles in children and adults"}]},"trialDetails":[{"nctId":"NCT04199104","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-05","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":511},{"nctId":"NCT06692959","phase":"PHASE2","title":"A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer","status":"RECRUITING","sponsor":"University of Southampton","startDate":"2025-06-16","conditions":"Colorectal Cancer","enrollment":44},{"nctId":"NCT06769698","phase":"PHASE2","title":"A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-03-31","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":120},{"nctId":"NCT06257212","phase":"PHASE4","title":"Live Vaccines and Innate Immune Training in COPD.","status":"COMPLETED","sponsor":"Josefin Eklöf","startDate":"2024-02-28","conditions":"Trained Innate Immunity, COPD","enrollment":60},{"nctId":"NCT05923970","phase":"","title":"Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2024-11-09","conditions":"Vaccination Failure, Vaccine Response Impaired","enrollment":200},{"nctId":"NCT00820820","phase":"NA","title":"IDA (Immunothérapie de la Dermatite Atopique) Adult - Immunotherapy in Atopic Dermatitis","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-01-09","conditions":"Atopic Dermatitis","enrollment":20},{"nctId":"NCT05523323","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-10-30","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":112},{"nctId":"NCT06387511","phase":"NA","title":"Increasing Measles Vaccination Coverage Through Supplementation With an SQ-LNS Incentive in Children Aged 6-23 Months","status":"COMPLETED","sponsor":"Alliance for International Medical Action","startDate":"2024-05-07","conditions":"Immunization Coverage, Vaccination, Nutrition","enrollment":3814},{"nctId":"NCT07103148","phase":"PHASE3","title":"A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-07-11","conditions":"Yellow Fever Immunization","enrollment":2440},{"nctId":"NCT07162480","phase":"PHASE2","title":"Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I)","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-12-28","conditions":"Adenoid Cystic Carcinoma","enrollment":28},{"nctId":"NCT07448727","phase":"","title":"Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT","status":"RECRUITING","sponsor":"University of Rome Tor Vergata","startDate":"2024-11-20","conditions":"Head & Neck Cancer, Head & Neck Squamous Cell Carcinoma","enrollment":25},{"nctId":"NCT07448116","phase":"PHASE1, PHASE2","title":"Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.","status":"RECRUITING","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2026-01-31","conditions":"Solid Advanced Tumor","enrollment":164},{"nctId":"NCT06824194","phase":"PHASE3","title":"Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-02-18","conditions":"Pneumococcal Immunization","enrollment":2320},{"nctId":"NCT07348692","phase":"PHASE3","title":"Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-20","conditions":"Pneumococcal Immunization, Healthy Volunteers","enrollment":896},{"nctId":"NCT06736041","phase":"PHASE3","title":"Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-12-18","conditions":"Pneumococcal Immunization","enrollment":1714},{"nctId":"NCT06291103","phase":"PHASE2, PHASE3","title":"Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Donor Specific Antibody After Kidney Transplantation (BELA-M-R)","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2026-03-01","conditions":"Kidney Transplant Rejection","enrollment":290},{"nctId":"NCT06041802","phase":"PHASE2","title":"A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-10-20","conditions":"Squamous Cell Carcinoma","enrollment":19},{"nctId":"NCT06824181","phase":"PHASE3","title":"Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-02-27","conditions":"Pneumococcal Immunization","enrollment":580},{"nctId":"NCT07408063","phase":"PHASE2","title":"A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2026-02-02","conditions":"Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT07406360","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-04-13","conditions":"Measles","enrollment":1209},{"nctId":"NCT01306006","phase":"PHASE4","title":"The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age","status":"COMPLETED","sponsor":"Bandim Health Project","startDate":"2011-02","conditions":"Mortality, Vaccines","enrollment":3500},{"nctId":"NCT01668745","phase":"PHASE4","title":"Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso.","status":"COMPLETED","sponsor":"Bandim Health Project","startDate":"2013-05-03","conditions":"Measles Vaccine","enrollment":4559},{"nctId":"NCT01644721","phase":"PHASE4","title":"Trial of Additional Measles Vaccine to Reduce Child Mortality","status":"COMPLETED","sponsor":"Bandim Health Project","startDate":"2012-07","conditions":"Measles Vaccine","enrollment":3750},{"nctId":"NCT03621670","phase":"PHASE3","title":"Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-07-27","conditions":"Infections, Meningococcal","enrollment":1196},{"nctId":"NCT07398664","phase":"PHASE2","title":"H101 Plus TACE for r/m HNSCC","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-02-15","conditions":"Head and Neck Squamous Cell Carcinoma, Oncolytic Virus, TACE","enrollment":20},{"nctId":"NCT03260023","phase":"PHASE1, PHASE2","title":"Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Transgene","startDate":"2017-09-01","conditions":"HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma","enrollment":143},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT07377656","phase":"PHASE2","title":"Strengthening HPV Immunization Through EPI Leveraged Delivery","status":"NOT_YET_RECRUITING","sponsor":"International Vaccine Institute","startDate":"2026-01-16","conditions":"HPV Vaccine","enrollment":115},{"nctId":"NCT06663436","phase":"PHASE2","title":"A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-11-13","conditions":"Diarrhoea","enrollment":200},{"nctId":"NCT07373093","phase":"","title":"Predictors of Measles Vaccine Hesitancy in New York State","status":"COMPLETED","sponsor":"Albany Medical College","startDate":"2025-07-01","conditions":"Measles Vaccination","enrollment":99},{"nctId":"NCT05622682","phase":"","title":"Vaccine Immune Recovery After Leukemia","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2022-09-28","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":89},{"nctId":"NCT07356050","phase":"","title":"Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2025-03-13","conditions":"Sickle Cell Disease, Measles Vaccination, Sickle Cell Anemia","enrollment":130},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT07354984","phase":"PHASE2","title":"A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-01","conditions":"Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT07338851","phase":"","title":"the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines","status":"NOT_YET_RECRUITING","sponsor":"China National Biotec Group Company Limited","startDate":"2026-01-30","conditions":"Polio, Measles, Rubella","enrollment":600},{"nctId":"NCT01856478","phase":"PHASE3","title":"LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-06-07","conditions":"Head and Neck Neoplasms","enrollment":340},{"nctId":"NCT06399003","phase":"PHASE3","title":"Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2024-06-28","conditions":"Measles-Mumps-Rubella","enrollment":1200},{"nctId":"NCT04521764","phase":"PHASE1","title":"A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-09-23","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Breast Adenocarcinoma","enrollment":54},{"nctId":"NCT07312604","phase":"NA","title":"A Pilot Study to Evaluate the Therapeutic Efficacy of Intra-Lesional Immunotherapy in Patients Aged 10-60 Years With Recalcitrant Tinea Cruris and Corporis","status":"RECRUITING","sponsor":"Abeer Mohamed Abdelaziz Elkholy","startDate":"2025-12-09","conditions":"Tinea Corporis, Tinea Cruris","enrollment":50},{"nctId":"NCT06816524","phase":"NA","title":"The Effects of Iron Treatment on Malaria and Measles Vaccine Response in Kenyan Infants With Iron Deficiency","status":"NOT_YET_RECRUITING","sponsor":"Nicole Stoffel","startDate":"2026-01-05","conditions":"Iron Deficiencies","enrollment":324},{"nctId":"NCT04997902","phase":"PHASE1, PHASE2","title":"Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)","status":"COMPLETED","sponsor":"Kura Oncology, Inc.","startDate":"2021-12-07","conditions":"HNSCC","enrollment":45},{"nctId":"NCT03172624","phase":"PHASE2","title":"Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-05-26","conditions":"Salivary Gland Cancer","enrollment":64},{"nctId":"NCT07267585","phase":"","title":"Unravelling the Measles Paradox (MISIA)","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2025-07-03","conditions":"MEASLES DISEASE","enrollment":300},{"nctId":"NCT06806137","phase":"PHASE3","title":"A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-05-15","conditions":"Chickenpox","enrollment":600},{"nctId":"NCT05073003","phase":"PHASE1","title":"A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-06","conditions":"Diarrhoea","enrollment":551},{"nctId":"NCT04428151","phase":"PHASE2","title":"Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-06","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":408},{"nctId":"NCT06855160","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-04-17","conditions":"Chickenpox","enrollment":900},{"nctId":"NCT06295731","phase":"PHASE2, PHASE3","title":"INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC","status":"RECRUITING","sponsor":"Inhibrx Biosciences, Inc","startDate":"2024-05-14","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":410},{"nctId":"NCT04067336","phase":"PHASE1, PHASE2","title":"First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Kura Oncology, Inc.","startDate":"2019-09-12","conditions":"Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia","enrollment":263},{"nctId":"NCT06597565","phase":"PHASE2","title":"A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-09-25","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":43},{"nctId":"NCT04209660","phase":"PHASE2","title":"Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-06-02","conditions":"Adenoid Cystic Carcinoma, Salivary Gland Cancer","enrollment":64},{"nctId":"NCT03564691","phase":"PHASE1","title":"Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-07-11","conditions":"Neoplasms","enrollment":470},{"nctId":"NCT07195032","phase":"PHASE4","title":"Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients","status":"RECRUITING","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2025-09-11","conditions":"Heart Transplant Infection Prevention","enrollment":60},{"nctId":"NCT05061420","phase":"PHASE2","title":"A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)","status":"TERMINATED","sponsor":"Sanofi","startDate":"2021-10-08","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":59},{"nctId":"NCT07186868","phase":"","title":"QL706 + Chemo ± Bevacizumab in Anti-PD-(L)1-Resistant R/M Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-10-15","conditions":"Recurrent Cervical Cancer, Metastatic Cervical Cancer","enrollment":25},{"nctId":"NCT05155579","phase":"PHASE1","title":"Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-05-14","conditions":"Malaria","enrollment":593},{"nctId":"NCT02098538","phase":"PHASE2","title":"Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-03","conditions":"Adenoid Cystic Carcinoma","enrollment":38},{"nctId":"NCT06038617","phase":"PHASE4","title":"Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2023-10-30","conditions":"Fever After Vaccination, Fever, Seizures Fever","enrollment":344},{"nctId":"NCT06771674","phase":"","title":"Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Hookipa Biotech GmbH","startDate":"2024-06-05","conditions":"Oropharyngeal Squamous Cell Carcinoma","enrollment":662},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT06686342","phase":"","title":"PDO Based Drug Sensitive Test in R/M HNSCC","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-03-26","conditions":"Head and Neck Squamous Cell Carcinoma, Patient Derived Organoid, Drug Sensitive Test in Vitro","enrollment":100},{"nctId":"NCT06686979","phase":"","title":"PDO Based Drug Sensitive Test in R/M SGC","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-03-26","conditions":"Salivary Gland Cancers, Patient Derived Organoid, Drug Sensitive Test in Vitro","enrollment":40},{"nctId":"NCT06331702","phase":"PHASE4","title":"Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)","status":"COMPLETED","sponsor":"Liaoning Chengda Biotechnology CO., LTD","startDate":"2024-03-02","conditions":"Japanese Encephalitis, Measles, Mumps","enrollment":408},{"nctId":"NCT06082167","phase":"PHASE2, PHASE3","title":"Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2024-06-07","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":600},{"nctId":"NCT06177301","phase":"PHASE3","title":"Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-12-01","conditions":"Nasopharyngeal Carcinoma","enrollment":266},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT05156970","phase":"PHASE2","title":"Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC","status":"COMPLETED","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2021-06-24","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma","enrollment":81},{"nctId":"NCT04220671","phase":"PHASE4","title":"Measles Vaccination at Health System Contacts","status":"ENROLLING_BY_INVITATION","sponsor":"Bandim Health Project","startDate":"2020-01-08","conditions":"Measles Vaccine, Hospital Admission, Mortality","enrollment":5400},{"nctId":"NCT06771193","phase":"","title":"Study on Disease Characteristics and Treatment in Locally Advanced or Recurrent / Metastatic Cervical Cancer in Italy","status":"RECRUITING","sponsor":"MSD Italia S.r.l.","startDate":"2024-12-17","conditions":"Cervical Cancer, Locally Advanced Cervical Cancer, Recurrent Cervical Cancer","enrollment":200},{"nctId":"NCT06935188","phase":"PHASE2","title":"Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC","status":"RECRUITING","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2025-04-17","conditions":"Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","enrollment":98},{"nctId":"NCT03071575","phase":"PHASE4","title":"Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2017-03-09","conditions":"Measles, Rubella, Rubella Syndrome, Congenital","enrollment":637},{"nctId":"NCT04055454","phase":"PHASE1","title":"A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001)","status":"COMPLETED","sponsor":"Themis Bioscience GmbH","startDate":"2019-09-26","conditions":"Lassa Virus Infection","enrollment":60},{"nctId":"NCT04282109","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX)","status":"COMPLETED","sponsor":"Grupo Español de Tratamiento de Tumores de Cabeza y Cuello","startDate":"2020-06-03","conditions":"Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","enrollment":141},{"nctId":"NCT05630846","phase":"PHASE2","title":"A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-12-14","conditions":"Measles; Mumps; Rubella; Chickenpox, Measles","enrollment":801},{"nctId":"NCT03114163","phase":"","title":"Observational Study of Nivolumab in Participants in Germany With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Progressing on or After Platinum-Based Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-05-12","conditions":"Head and Neck Cancer","enrollment":485},{"nctId":"NCT00505063","phase":"PHASE2","title":"Prospective Trial of Vaccine Responses in Childhood Cancer Survivors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-07-10","conditions":"Childhood Cancer, Multiple Diseases","enrollment":76},{"nctId":"NCT06802835","phase":"PHASE1, PHASE2","title":"EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-Sen University Cancer Center","startDate":"2025-05","conditions":"Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma, Metastatic Nasopharyngeal Carcinoma","enrollment":148},{"nctId":"NCT05930951","phase":"PHASE1","title":"Study of OBT076 Associated or Not in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck","status":"TERMINATED","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2023-11-29","conditions":"Adenoid Cystic Carcinoma of the Head and Neck","enrollment":19},{"nctId":"NCT06456788","phase":"","title":"Barriers and Facilitators to MMR Vaccination Among Healthcare Workers","status":"COMPLETED","sponsor":"King's College London","startDate":"2024-09-12","conditions":"Measles","enrollment":23},{"nctId":"NCT05830539","phase":"PHASE1, PHASE2","title":"IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients","status":"COMPLETED","sponsor":"InxMed (Shanghai) Co., Ltd.","startDate":"2022-03-10","conditions":"Locally Advanced or Metastatic Solid Tumors","enrollment":68},{"nctId":"NCT06946407","phase":"NA","title":"Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma","status":"RECRUITING","sponsor":"FengYan Jin","startDate":"2022-12-02","conditions":"Primary Central Nervous System Lymphoma (PCNSL), CNS Lymphoma Treatment","enrollment":41},{"nctId":"NCT06920069","phase":"PHASE4","title":"Study of Concomitant Administration of the sIPV and DTaP or MMR","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2025-05-15","conditions":"Polio, Diphteria, Tetanus and Pertussis, MMR Vaccine","enrollment":2640},{"nctId":"NCT06064877","phase":"PHASE3","title":"A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"AVEO Pharmaceuticals, Inc.","startDate":"2024-01-11","conditions":"Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":410},{"nctId":"NCT06869473","phase":"PHASE2","title":"Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2025-02-20","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer","enrollment":67},{"nctId":"NCT05743270","phase":"PHASE2","title":"Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN","status":"WITHDRAWN","sponsor":"Replimune Inc.","startDate":"2024-01-30","conditions":"Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT06740630","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-01-10","conditions":"Chickenpox","enrollment":1840},{"nctId":"NCT03547271","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-12-14","conditions":"Meningococcal Infections","enrollment":1660},{"nctId":"NCT05084508","phase":"PHASE2","title":"A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-02-03","conditions":"Chickenpox","enrollment":800},{"nctId":"NCT06815835","phase":"PHASE3","title":"Non-interference Study of MR and Yellow Fever Vaccines Among Bangladeshi Infants Aged 9-12 Months","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-04-01","conditions":"Measles, Rubella, Yellow Fever","enrollment":1530},{"nctId":"NCT04857164","phase":"PHASE2","title":"Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China","status":"RECRUITING","sponsor":"Yuankai Shi","startDate":"2021-04-30","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":150},{"nctId":"NCT06197776","phase":"","title":"Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-07-15","conditions":"Multi-omics Technique, Nasopharyngeal Carcinoma, Recurrent and Metastatic Nasopharyngeal Carcinoma","enrollment":50},{"nctId":"NCT06693895","phase":"PHASE3","title":"A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-11-26","conditions":"Chickenpox","enrollment":750},{"nctId":"NCT06719479","phase":"PHASE2, PHASE3","title":"A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.).","status":"NOT_YET_RECRUITING","sponsor":"SUNHO（China）BioPharmaceutical CO., Ltd.","startDate":"2025-01-01","conditions":"NPC, HNSCC, Recurrence","enrollment":60},{"nctId":"NCT04475081","phase":"PHASE3","title":"Use of a Live Attenuated Vaccine as an Immune-based Preventive Against COVID-19-associated Sepsis","status":"COMPLETED","sponsor":"Louisiana State University Health Sciences Center in New Orleans","startDate":"2020-09-22","conditions":"Sepsis Syndrome","enrollment":50},{"nctId":"NCT05614791","phase":"","title":"Evaluation of Pediatric Measles Cases in 2019: Single-Center Experience","status":"COMPLETED","sponsor":"Marmara University","startDate":"2019-01-01","conditions":"Measles","enrollment":40},{"nctId":"NCT06601335","phase":"PHASE3","title":"A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)","status":"RECRUITING","sponsor":"Akeso","startDate":"2024-10-30","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":510},{"nctId":"NCT06667206","phase":"PHASE2","title":"Earlier Prime-BOOST Schedule to Improve MEasles Protection in High Burden Settings","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2023-11-15","conditions":"Measles","enrollment":450},{"nctId":"NCT05467839","phase":"NA","title":"Evaluation of Efficacy of Microneedling and Topical Methotrexate Versus Microneedling and Topical 5-flourouracil in Treatment of Vitillgo Patients","status":"COMPLETED","sponsor":"Sohag University","startDate":"2022-07-31","conditions":"Vitiligo","enrollment":30},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT05401448","phase":"EARLY_PHASE1","title":"Non-specific Effects of FLU-MMR Vaccines in Adults","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2021-06-01","conditions":"COVID-19","enrollment":638}],"_emaApprovals":[],"_faersSignals":[{"count":5,"reaction":"DRUG HYPERSENSITIVITY"},{"count":5,"reaction":"DRUG INTOLERANCE"},{"count":5,"reaction":"FEBRILE NEUTROPENIA"},{"count":5,"reaction":"GASTROINTESTINAL DISORDER"},{"count":4,"reaction":"VARICELLA ZOSTER VIRUS INFECTION"},{"count":2,"reaction":"ANURIA"},{"count":2,"reaction":"ENCEPHALOPATHY"},{"count":2,"reaction":"FEBRILE CONVULSION"},{"count":2,"reaction":"GRANULOMA"},{"count":2,"reaction":"INFLUENZA"}],"_approvalHistory":[],"publicationCount":2864,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Measles vaccine (MeasBio) 0.5 mL","MeasBio®"],"phase":"marketed","status":"active","brandName":"Measles vaccine","genericName":"Measles vaccine","companyName":"Bandim Health Project","companyId":"bandim-health-project","modality":"Biologic","firstApprovalDate":"","aiSummary":"The measles vaccine stimulates the immune system to produce antibodies and cellular immunity against the measles virus, preventing infection and disease. Used for Prevention of measles in children and adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}